Company

COMPANY

About Profound

Partners

Profound Medical develops customizable, incision-free therapies which combine real-time Magnetic Resonance (“MR”) imaging, thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue

Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. We believe TULSA-PRO® is demonstrating to be a flexible technology in customizable prostate ablation. TULSA-PRO® is CE marked and received 510(k) clearance from the U.S. Food and Drug Administration in August 2019.

Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China Food and Drug Administration for the non-invasive treatment of uterine fibroids. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

In February, 2016, we entered into a Strategic Agreement with Siemens.

On June 30, 2017, we announced a Definitive Agreement with Philips to Expand Collaboration and Acquire Sonalleve MR-HIFU Business.

On May 11, 2016, we signed a Sales and Marketing Agreement with Philips.

In July 2015, we announced a Joint Development Agreement with Philips.

On December 2020, we entered into a Strategic Agreement with GE

Leadership Team

We have a seasoned leadership team with extensive experience in commercialization of ablation technologies.

Board of Directors

Profound Medical Inc., receives guidance and governance from a Board of Directors that embodies deep experience in the medical device industry and a strong history of success.

Clinical Advisory Board

Profound Medical’s research and clinical trials are further informed by the considerable collective expertise of well-experienced clinicians, specializing in urology and radiology.

Mark Emberton, OBE FMedSci
Dean, Faculty of Medical Sciences, University College London
Professor of Interventional Oncology, Division of Surgery and Interventional Science, UCL
Honorary Consultant Urologist, UCLH

Michael Fabrizio MD FACS
Professor of Urology
Eastern Virginia Medical School
Urology of Virginia, Past President
Co-Founder, The Atlantic Clinic

Pejman Ghanouni, MD, PhD

Associate Professor of Radiology and, by courtesy, of Neurosurgery, of Obstetrics and Gynecology and of Urology.

Y. Mark Hong, MD

Board-certified Urologist and founder of Integrative Urology in Phoenix, Arizona.

Naveen Kella, MD

Board Certified Urologist and Director at the Urology Place

Laurence Klotz, MD, FRCSC, CM

Professor of Surgery, University of Toronto
Sunnybrook Chair of Prostate Cancer Research
Chairman, Canadian Urology Research Consortium

Aytekin Oto, MD

Chair, Department of Radiology, University of Chicago
Chief Physician, Head of the Faculty Practice Plan and Dean for Clinical Affairs
Professor of Radiology, University of Chicago
Professor of Surgery, University of Chicago

Neal Shore, MD,FACS

Chief Medical Officer, Surgical Oncology/Urology, Genesis Care, US, Medical Director, Carolina Urologic Research Center.

Preston Sprenkle, MD

Director, Urology Research Fellowship, Urology, Yale School of Medicine, New Haven, CT
Director, Urologic Oncology Clinical Fellowship Program, Urology, Yale School of
Medicine, New Haven, CT
Division Chief, Division of Urology at VA Connecticut Healthcare System, Urology, VA Connecticut Healthcare System, West Haven, CT
Co-Chair, Cancer Liaison Committee, Oncology, VA Connecticut Healthcare
System, West Haven, CT
Co-Chair, NCCN Guidelines Committee on Prostate Cancer Early Detection,
National Comprehensive Cancer Network (NCCN), Plymouth Meeting, PA

Edward Steiner, MD

Medical Director and Chief of the WellSpan York Prostate Care Center
Ex-Chairman of Imaging and Radiation Oncology at WellSpan York Hospital PA

Careers

Seeking qualified, committed professionals to join our team.

We are a young, creative and passionate organization committed to making a difference in men’s health with our unique procedure for the ablation of cancerous and non-cancerous prostate tissue.

Our mission is to Profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives.

Changing the standard of care is part of our fabric. We are a group of energetic, problem-solvers focused on innovation, and looking to change the world. If you want to make a Profound impact with your career, here is your chance.

We are committed to fostering an inclusive, accessible environment where all employees feel respected and supported. We are dedicated to building a diverse workforce and creating an environment where every employee has the opportunity to reach his/her full potential.

We strive to promote diversity and equal opportunity in the workplace and encourage applications from all qualified individuals.

If selected to participate in the recruitment, selection and/or assessment process, please inform Human Resources of the nature of any accommodation(s) that you may require.

This page lists all current job opportunities which our current employees and the general public can apply for. Those individuals who meet the requirements for a position and are interested in applying should submit their resume and cover letter to [email protected]

Thank you for considering Profound Medical.